Q&A: The evolving role of antibody-drug conjugates in oncology

The oncology field is rapidly advancing with the development of antibody-drug conjugates (ADCs), offering new hope for precision medicine. Dr. Kate Sasser from Tempus led a discussion with Dr. Daniel Johnson, Dr. Funda Meric-Bernstam, and Dr. Kellogg Parsons on the potential of ADCs, the challenges in targeting tumor antigens, and the future of cancer treatment.